SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,608

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
24-12-01	12.17 ¥	-0.08%	14,745,080
24-11-29	12.18 ¥	+1.50%	14,793,500
24-11-28	12.00 ¥	-1.88%	15,537,870
24-11-27	12.23 ¥	+1.49%	12,460,480
24-11-26	12.05 ¥	+0.42%	12,128,290

End-of-day quote Shanghai S.E., December 01, 2024

More quotes

Income Statement and Estimates

income-statement-evolution-chart SHANGHAI-SHYNDEC-PHARMACE

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

2

Last Close Price

12.17CNY

Average target price

19.52CNY

Spread / Average Target

+60.39%

Consensus

Profit revisions

estimates-change-chart SHANGHAI-SHYNDEC-PHARMACE

Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart SHANGHAI-SHYNDEC-PHARMACE

Company calendar

End-of-day quote Shanghai S.E. Other stock markets 2024-12-02			5-day change	1st Jan Change
12.17 ^CNY	-0.08%		+0.58%	+24.31%

11-27	Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	MT
11-27	Shanghai Shyndec Pharmaceutical CFO Resigns	MT

Capitalization	16.32B 2.25B 2.14B 1.99B 1.77B 3.16B 191B 3.46B 24.61B 9.16B 78.19B 8.47B 8.28B 339B	P/E ratio 2024 *	14x	P/E ratio 2025 *	11.8x
Enterprise value	16.32B 2.25B 2.14B 1.99B 1.77B 3.16B 191B 3.46B 24.61B 9.16B 78.19B 8.47B 8.28B 339B	EV / Sales 2024 *	1.36x	EV / Sales 2025 *	1.27x
Free-Float	41.74%	Yield 2024 *	0.82%	Yield 2025 *	8.92%

Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	11-27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	11-26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	10-28	CI
China Approves Shyndec Pharmaceutical's Listing Application for Epilepsy Drug Ingredient	09-05	MT
Shyndec Pharmaceutical Gets Nod to Add Specification to Pravastatin Sodium Tablets	08-30	MT
Shyndec Pharmaceutical's H1 Profit Soars 108%, Operating Income Slips 8%	08-28	MT
Shyndec Pharmaceutical's Chairman, President Resign	08-28	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-27	CI
Shanghai Shyndec Pharmaceutical Antibiotic Drug Passes Drug Consistency Evaluation	08-12	MT
Shanghai Shyndec Pharmaceutical's Chest Pain Drug Passes China's Drug Evaluations	07-31	MT
Shyndec Pharmaceutical's Unit Gets Nod to Amend Lipoic Acid Injection's Specification	07-19	MT
Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	07-12	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	07-09	MT

1 day	-0.08%
1 week	+0.58%
Current month	-0.08%
1 month	+1.16%
3 months	+7.51%
6 months	+6.47%
Current year	+24.31%

Shanghai Shyndec Pharmaceutical Co., Ltd. Stock

Equities

600420

CNE000001JG2

Pharmaceuticals

Valuation: Shanghai Shyndec Pharmaceutical Co., Ltd.

Chart: Shanghai Shyndec Pharmaceutical Co., Ltd.

Latest news: Shanghai Shyndec Pharmaceutical Co., Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Shanghai Shyndec Pharmaceutical Co., Ltd.

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Director	Title	Age	Since
Qian Yin Jing IRC	Investor Relations Contact	44	2019-09-12
Zhong Xi Zhang SEC	Corporate Secretary	48	2024-03-27

Manager	Title	Age	Since
Xiang Dong Yu BRD	Director/Board Member	60	2019-01-30
Peng Wang BRD	Director/Board Member	42	2022-11-27
Yong Liu BRD	Director/Board Member	55	2021-05-16

	2024 *	2025 *
Net sales	12.02B 1.66B 1.57B 1.46B 1.31B 2.33B 140B 2.55B 18.13B 6.75B 57.6B 6.24B 6.1B 250B	12.88B 1.78B 1.69B 1.57B 1.4B 2.49B 150B 2.73B 19.41B 7.23B 61.68B 6.68B 6.53B 268B
Net income	1.17B 162M 154M 143M 127M 227M 13.7B 249M 1.77B 658M 5.62B 608M 595M 24.38B	1.38B 190M 180M 168M 150M 266M 16.07B 292M 2.08B 773M 6.59B 714M 698M 28.61B
Net Debt	-	-

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi. ($)
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	-0.08%	+0.58%	+16.24%	+25.33%	2.26B
MERCK KGAA	+0.21%	-0.49%	-12.16%	-33.06%	64.96B
KYOWA KIRIN CO. LTD.	-0.30%	-1.76%	+2.38%	-23.38%	8.41B
YUHAN CORPORATION	+1.99%	+2.26%	+100.95%	+136.14%	6.18B
HALOZYME THERAPEUTICS, INC.	-0.67%	+0.67%	+19.95%	+45.00%	6.13B
SK BIOPHARMACEUTICALS CO., LTD.	-0.68%	+7.65%	+20.40%	+8.11%	5.79B
BETTA PHARMACEUTICALS CO., LTD.	+2.89%	+15.38%	+0.99%	-30.45%	3.2B
SUPERNUS PHARMACEUTICALS, INC.	+0.44%	+1.58%	+30.45%	+17.61%	2.02B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+3.52%	+6.92%	-26.64%	+39.70%	2.01B
VELOXIS PHARMACEUTICALS A/S	-.--%	-.--%	-	-	1.64B
Average	+0.73%	+2.30%	+16.95%	+20.56%	10.26B
Weighted average by Cap.	+0.32%	+0.67%	+1.41%	-10.94%